Mineralys Therapeutics (MLYS) Accumulated Expenses (2022 - 2026)
Mineralys Therapeutics (MLYS) posted Accumulated Expenses of $13.6 million for Q1 2026, up 3.86% sequentially from $13.1 million in Q4 2025, and up 4.53% YoY from $13.0 million in Q1 2025.
Mineralys Therapeutics (MLYS) Accumulated Expenses (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Accumulated Expenses for 5 years, with the latest figure at $13.6 million in Q1 2026.
- Quarterly Accumulated Expenses rose 4.53% year-over-year to $13.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.6 million (up 4.53% YoY) and the FY2025 annual result came in at $13.1 million, down 7.56% from the prior year.
- Accumulated Expenses advanced to $13.6 million in Q1 2026 per MLYS's latest filing, from $13.1 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $28.2 million in Q3 2024 and troughed at $4.0 million in Q2 2023.
- A 5-year average of $14.4 million and a median of $13.3 million in 2025 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses jumped 565.42% in 2024, then slipped 28.78% in 2025.
- Over 5 years, Accumulated Expenses stood at $6.2 million in 2022, then soared by 60.41% to $9.9 million in 2023, then surged by 43.38% to $14.2 million in 2024, then slipped by 7.56% to $13.1 million in 2025, then rose by 3.86% to $13.6 million in 2026.
- According to Business Quant data, Accumulated Expenses over the past three periods registered $13.6 million, $13.1 million, and $22.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.25 Mn |
| Mar 31, 2026 | 13.60 Mn |
| Dec 31, 2025 | 13.10 Mn |
| Sep 30, 2025 | 22.40 Mn |
| Jun 30, 2025 | 19.01 Mn |
| Mar 31, 2025 | 13.01 Mn |
| Dec 31, 2024 | 14.17 Mn |
| Sep 30, 2024 | 28.22 Mn |
| Jun 30, 2024 | 26.69 Mn |
| Mar 31, 2024 | 14.94 Mn |
| Dec 31, 2023 | 9.88 Mn |
| Sep 30, 2023 | 7.97 Mn |
| Jun 30, 2023 | 4.01 Mn |
| Mar 31, 2023 | 8.17 Mn |
| Dec 31, 2022 | 6.16 Mn |